Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma Unsuitable for SCT
NCT01990534Phase 4Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Mar 2014
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 7
01
Overview
A Phase 4 trial of brentuximab vedotin in Classical Hodgkin Lymphoma (cHL), sponsored by Millennium Pharmaceuticals. Started Mar 2014; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
Classical Hodgkin Lymphoma (cHL)
Beyond the preview
Go deeper on NCT01990534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01990534.